You have free access to this content

Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period

  1. Jean-Pierre Cazenave,
  2. Hervé Isola,
  3. Chantal Waller,
  4. Isabelle Mendel,
  5. Daniel Kientz,
  6. Michel Laforêt,
  7. Jean-Pierre Raidot,
  8. Gérard Kandel,
  9. Marie-Louise Wiesel,
  10. Laurence Corash

Article first published online: 16 SEP 2010

DOI: 10.1111/j.1537-2995.2010.02873.x

Issue

Transfusion

Transfusion

Volume 51, Issue 3, pages 622–629, March 2011

Additional Information

How to Cite

Cazenave, J.-P., Isola, H., Waller, C., Mendel, I., Kientz, D., Laforêt, M., Raidot, J.-P., Kandel, G., Wiesel, M.-L. and Corash, L. (2011), Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion, 51: 622–629. doi: 10.1111/j.1537-2995.2010.02873.x

Author Information

  1. >From the Etablissement Français du Sang (EFS)–Alsace, INSERM UMR-S949, and the Université de Strasbourg, Strasbourg, France; and Cerus Corp., Concord, California.

*Jean-Pierre Cazenave, Etablissement Français du Sang-Alsace, 10 rue Spielmann, BP 36, 67065 Strasbourg Cedex, France; e-mail: jeanpierre.cazenave@efs-alsace.fr.

Publication History

  1. Issue published online: 9 MAR 2011
  2. Article first published online: 16 SEP 2010
  3. Received for publication March 31, 2010; revision received July 9, 2010, and accepted July 12, 2010.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (296K)

REFERENCES

  • 1
    Alvarez-Larrán A, Del Río J, Ramírez C, Albo C, Peña F, Campos A, Cid J, Muncunill J, Sastre JL, Sanz C, Pereira A. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004;86:246-51.
    Direct Link:
  • 2
    de la Rubia J, Arriaga F, Linares D, Larrea L, Carpio N, Marty ML, Sanz MA. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 2001;114:721-3.
    Direct Link:
  • 3
    Andreu G, Morel P, Forestier F, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998. Transfusion 2002;42:1356-64.
    Direct Link:
  • 4
    Cazenave JP, Aleil B, Wiesel ML, Laforet M, Isola H. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang 2004;86:201-2.
    Direct Link:
  • 5
    Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin LS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52.
    Direct Link:
  • 6
    TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-9.
  • 7
    Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G. The threshold for prophylactic platelet transfusions in adults with acute myelogenous leukemia. N Engl J Med 1997;337:1870-5.
  • 8
    van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
  • 9
    McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-41.
  • 10
    Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-23.
    Direct Link:
  • 11
    Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5,106 platelet transfusions using components prepared with photochemical pathogen inactivation treatment. Transfusion 2008;48:1061-71.
    Direct Link:
  • 12
    Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H, Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L, Cazenave JP. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009;49:1083-91.
    Direct Link:
  • 13
    Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
    Direct Link:
View Full Article (HTML) Get PDF (296K)